Status:
COMPLETED
Hydroxychloroquine in Cystic Fibrosis
Lead Sponsor:
Vanderbilt University
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
16+ years
Phase:
PHASE1
Brief Summary
Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.
Detailed Description
Open label study of effect of hydroxychloroquine on inflammation, bacterial burden and exhaled breath condensate pH in patients with cystic fibrosis. Patients with cystic fibrosis, 16 years or older a...
Eligibility Criteria
Inclusion
- Male or female between 16 years and 65 years of age.
- Confirmed diagnosis of CF based on the following criteria:
- i. positive sweat chloride 60 mEq/liter (by pilocarpine iontophoresis) and/or ii. a genotype with two identifiable mutations consistent with CF, and iii. accompanied by one or more clinical features consistent with the CF phenotype
- FEV1 50% predicted value (subjects 16- \<18 years of age) or 40% predicted value (subjects 18 years of age)
- Clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within the 14 days prior to Visit 1 (Day 0)
- Ability to reproducibly perform spirometry and peak flow measurements
- Ability to understand and sign a written informed consent or assent and comply with the requirements of the study
Exclusion
- Use of an investigational agent within the 4-week period prior to Visit 1
- Chronic daily use of ibuprofen or other NSAIDs, or systemic corticosteroids, or any oral diabetic or hypoglycemic agent within the 4 weeks prior to Visit 1 or acute usage within 72 hours prior to Visit 1
- History of hypersensitivity to beta-agonists
- History of hypersensitivity to hydroxychloroquine or chloroquine
- Oxygen saturation \< 92% on room air at Visit 1
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- History of hemoptysis 30 cc per episode during the 30 days prior to Visit 1
- Significant history of hepatic, cardiovascular, renal, neurological, hematologic, or peptic ulcer disease
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00311883
Start Date
March 1 2006
End Date
December 1 2007
Last Update
January 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232